SU

SUN PHARMACEUTICAL INDUSTRIES LTD

  • CIK: 0001197089
  • EIN: 00-0000000
  • Business address: 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST), India, 400 093

Information

  • Mailing address
    17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST), K7, 400 093
  • Phone
    01191228212128
  • State location
    India
  • State of incorporation
    N/A
  • Fiscal year end
    March 31
  • SIC
    2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
  • Filings
    N/A

About SUN PHARMACEUTICAL INDUSTRIES LTD

SUN PHARMACEUTICAL INDUSTRIES LTD (CIK: 0001197089) is an American company incorporated in the state of India. Head office is located at 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST), India, 400 093. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. SUN PHARMACEUTICAL INDUSTRIES LTD is a public company and trade via Over-The-Counter (OTC).

Ownership

Updating!

Stock Chart

Coming soon!

Jobs

Coming soon!

Recent SEC Filings

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by SUN PHARMACEUTICAL INDUSTRIES LTD

Filings Format Description Filed/Effective File/Film Number
SC 13D/A Document

Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0000950103-24-000736 ( Act) Size: 402 KB		 Jan-17-2024

SC 13D/A Document

Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0000950103-23-017375 ( Act) Size: 126 KB		 Dec-11-2023

SC 13D/A Document

Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0000950103-23-007957 ( Act) Size: 141 KB		 May-26-2023

SC TO-T/A Document

Amendment to Third party tender offer statement

Acc-no: 0001193125-23-060807 ( Act) Size: 82 KB		 Mar-06-2023

SC TO-T/A Document

Amendment to Third party tender offer statement

Acc-no: 0001193125-23-048734 ( Act) Size: 39 KB		 Feb-24-2023

SC TO-T Document

Third party tender offer statement

Acc-no: 0001193125-23-022120 ( Act) Size: 3060 KB		 Feb-02-2023

SC TO-C Document

Written communication relating to an issuer or third party tender offer

Acc-no: 0001193125-23-021678 ( Act) Size: 187 KB		 Feb-01-2023

SC TO-C Document

Written communication relating to an issuer or third party tender offer

Acc-no: 0001193125-23-020480 ( Act) Size: 62 KB		 Jan-31-2023

SC TO-C Document

Written communication relating to an issuer or third party tender offer

Acc-no: 0000950103-23-000746 ( Act) Size: 568 KB		 Jan-19-2023

SC 13D/A Document

Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0000947871-22-000951 ( Act) Size: 214 KB		 Sep-08-2022

SC 13D/A Document

Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0001104659-20-069253 ( Act) Size: 86 KB		 Jun-03-2020

SC 13D/A Document

Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0001104659-20-041157 ( Act) Size: 97 KB		 Mar-31-2020

SC 13D Document

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0001144204-17-060942 ( Act) Size: 179 KB		 Nov-27-2017

4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0000899243-17-027391 (34 Act) Size: 19 KB		 Nov-24-2017

001-38293

171221619
SC TO-C Document

Written communication relating to an issuer or third party tender offer

Acc-no: 0000947871-15-000654 ( Act) Size: 70 KB		 Sep-15-2015

SC 13D/A Document

Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0000947871-13-000755 ( Act) Size: 262 KB		 Nov-27-2013

SC 13D/A Document

Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0000947871-13-000074 ( Act) Size: 240 KB		 Feb-08-2013

SC 13D/A Document

Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0001104659-12-086188 ( Act) Size: 132 KB		 Dec-26-2012

3 Document

Initial statement of beneficial ownership of securities

Acc-no: 0001104659-12-078972 (34 Act) Size: 15 KB		 Nov-19-2012

001-31533

121215521
SC 13D/A Document

Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

Acc-no: 0000947871-12-000592 ( Act) Size: 665 KB		 Aug-13-2012

Recent 20 filings. View all SUN PHARMACEUTICAL INDUSTRIES LTD filings

Reviews

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Frequently Asked Questions

Tags:

  • SUN PHARMACEUTICAL INDUSTRIES LTD overview
  • SUN PHARMACEUTICAL INDUSTRIES LTD job
  • SUN PHARMACEUTICAL INDUSTRIES LTD stock
  • SUN PHARMACEUTICAL INDUSTRIES LTD ownership
  • SUN PHARMACEUTICAL INDUSTRIES LTD CEO
  • SUN PHARMACEUTICAL INDUSTRIES LTD documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.

Orther Companies

Contineum Therapeutics, Inc.
Update: Mar 16, 2024
Cuprina Holdings (Cayman) LTD
Update: Mar 08, 2024
APRINOIA Therapeutics Inc.
Update: Jan 27, 2024
Zhengye Biotechnology Holding Ltd
Update: Jan 10, 2024
Alto Neuroscience, Inc.
Update: Nov 28, 2023
Mural Oncology plc
Update: Nov 02, 2023

Latest News

SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate Conflicts of Interest
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
SEC Press Releases  Nov 17, 2023 2045 Views
Charter Communications to Pay $25 Million Penalty for Unauthorized Stock Buybacks
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Press Releases  Nov 15, 2023 3938 Views
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Press Releases  Nov 15, 2023 3343 Views
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries for Falsifying Documents While Raising $70 Million From Investors
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Press Releases  Nov 10, 2023 3373 Views
SEC Charges Royal Bank of Canada with Internal Accounting Controls Violations
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Press Releases  Nov 03, 2023 2336 Views
SEC Charges President/CCO of Prophecy Asset Management Advisory Firm with Multi-Year Fraud
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Press Releases  Nov 03, 2023 4567 Views
SEC Adopts Rules for the Registration and Regulation of Security-Based Swap Execution Facilities
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Press Releases  Nov 02, 2023 4937 Views
SEC Charges Crypto Company SafeMoon and its Executive Team for Fraud and Unregistered Offering of Crypto Securities
SEC Charges Crypto Company SafeMoon and its Executive Team for...
SEC Press Releases  Nov 01, 2023 3062 Views
SEC Charges Four Long Island Men with Perpetrating $2 Million “Free-Riding” Scheme
SEC Charges Four Long Island Men with Perpetrating $2 Million...
SEC Press Releases  Nov 01, 2023 4126 Views

© 2022 CompaniesBIO.Com. All rights reserved. Operated by